

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A31; B44, B35; Cw4, - ; DR1, DR7; DQ2, DQ5

Summary of Results					Summary of Results				
Total tested	42	44	44	43	29	29	29	29	
Positive	35	0	1	20	3	0	0	14	
Negative	7	44	43	23	26	29	29	15	
Not Tested	8	8	8	8	0	1	1	1	
% Positive	83.3%	0.0%	2.3%	46.5%	10.3%	0.0%	0.0%	48.3%	
% Negative	16.7%	100.0%	97.7%	53.5%	89.7%	100.0%	100.0%	51.7%	
Consensus	Positive	Negative	Negative	Not Assessed	Negative	Negative	Negative	Not Assessed	
HLA Antibody (Defined By CDC)	A2, B17	DR3	DR3	B14+					
Without DTT					With DTT (Not assessed)				
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
112	NT	NT	NT	NT					Internal controls non-satisfactory
114	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	Positive	Negative	Positive	Positive	Negative	Negative	Negative	Positive	
117	Positive	Negative	Negative	Equivocal					Very bad viability
119	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
120	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative					Few cells, but 100% viability
128	Positive	Negative	Negative	Negative	Negative	NT	NT	NT	
136	NT	NT	NT	NT					
139	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
145	Positive	Negative	Negative	Positive					
147	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
149	Positive	Negative	Negative	Positive					
154	Positive	Negative	Negative	Negative					
159	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
174	Uninterpretable	Negative	Negative	Negative	Uninterpretable	Negative	Negative	Negative	10-15% dead cells found in the negative and diluent controls hindered the interpretation, particularly for serum 1
181	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
189	NT	NT	NT	NT					Not tested due to low cell count
190	Positive	Negative	Negative	Negative					
193	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
195	NT	NT	NT	NT					
197	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
202	NT	NT	NT	NT					
204	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
206	Positive	Negative	Negative	Positive					
209	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	NT	NT	NT	NT					
216	Positive	Negative	Negative	Negative					
223	Positive	Negative	Negative	Negative					
227	NT	NT	NT	NT					Not tested due to poor viability
229	NT	NT	NT	NT					Not tested due to low cell viability
232	Negative	Negative	Negative	Negative					
235	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Cell viability was very low
238	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
243	Positive	Negative	Negative	Positive					
245	Equivocal	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
252	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
259	Positive	Negative	Negative	Negative					
260	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
262	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
271	Positive	Negative	Negative	Positive					
284	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
293	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	
294	Negative	Negative	Negative	Positive					
297	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	

PLEASE NOTE: NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		pre C'	post C'	
112	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	Yes		No	90		One Lambda	30	60	Stain Fix
114	4	1	1	2	1	1	1	2	27-Mar	27-Mar		Yes	Yes			One Lambda	30	60	EB/AO
116	8	1	2	2	1	1	1	4	26-Mar	27-Mar		Yes	No	90		Cedarlane	20	60	EB/AO
117	8	1	1						27-Mar	28-Mar	Yes		No	60		Pel-Freeze	80	120	Eosin
119	6	1	1	4	1	1	1	1	26-Mar	26-Mar	Yes		No	95		Biorad	30	60	Eosin
120	4	1	1	1	1	1	1	1	27-Mar	27-Mar		Yes	Yes	100		Servibio	30	60	EB/AO
126									26-Mar	26-Mar		Yes	Yes	100		Cedarlane	30	40	EB/AO
128	8	1	1	1	1				26-Mar	28-Mar	Yes		No	90		One Lambda	45	90	
136	NT	NT	NT	NT					26-Mar	27-Mar				65					
139	4	1	1	1	1	1	1	1	31-Mar	31-Mar	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	6	1	1	1	6	1	1	1	27-Mar	28-Mar		Yes	Yes			Cedarlane	30	60	Eosin
145	8			4-6					26-Mar	27-Mar		Yes	Yes	100		Invitrogen	45	45	EB/AO
147	6	1	1	8	1	1	1	6	26-Mar	26-Mar		Yes	Yes	100		In-house	30	60	Fluoroquench
149	6-8			2-4					27-Mar	28-Mar	Yes			85			60	60	Eosin
154	6	1	1	1					25-Mar	27-Mar		Yes	No	70		Cedarlane	30	60	Eosin
159	8	1	1	1	1	1	1	1	27-Mar	27-Mar		Yes	Yes	95		In-house	30	60	Fluoroquench
162	8								26-Mar	27-Mar		Yes	Yes	100		Cedarlane	60	60	
164									26-Mar	27-Mar		Yes	Yes	80		Servibio	45	90	EB/AO
169	1	1	1	1	1	1	1	1	27-Mar	28-Mar		Yes	No	60		One Lambda	35	75	Fluoroquench
174									31-Mar	31-Mar	Yes			99		One Lambda	60	120	Eosin
181	8			2				2	26-Mar	27-Mar	Yes		No	100		Cedarlane	30	45	EB
186	4	0	0	4	0	0	0	4	27-Mar	27-Mar		Yes	Yes	99		Invitrogen	30	60	EB
189	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
190	80%	2%	2%	2%					26-Mar	27-Mar		Yes	Yes	99		Cedarlane	30	60	Fluoroquench
193	6	1	1	1	1	1	1	1	26-Mar	26-Mar	Yes	Yes	No	99	99	Cedarlane	30	60	Fluoroquench
194	6	1	1	6	1	1	1	4	26-Mar	26-Mar		Yes	Yes	95			30	45	Fluoroquench
195	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
197	Weak				Weak				27-Mar	28-Mar		Yes	Yes	90	90	One Lambda	30	60	Fluoroquench
202																			
204	6	1	1	4	1	1	1	4	26-Mar	26-Mar		Yes	No	95		Cedarlane	45	90	Fluoroquench
206	8	1	1	4					26-Mar	27-Mar		Yes	Yes	90		Cedarlane	30	45	Fluoroquench
209	6								27-Mar	27-Mar	Yes		No	98		Ingen	30	60	Fluoroquench
210																			
216	6	2	2	2					27-Mar	27-Mar	Yes		No	90		Biorad	30	60	PI
223	8	1	1	1					27-Mar	28-Mar		Yes	Yes	100		Biorad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	26-Mar		Yes	Yes	70		Immucor	30	60	Fluoroquench
229	NT	NT	NT	NT	NT	NT	NT	NT	02-Apr	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
232	0%	0%	0%	0%					01-Apr	02-Apr		Yes	Yes	95		Biorad	45	60	EB/AO
235	1	1	1	8	1	1	1	6	26-Mar	26-Mar	Yes		No	75		Biorad	30	60	Eosin
238	8	1	1	6	1	1	1	6	26-Mar	27-Mar	Yes	Yes	Yes	95	95	Invitrogen	45	90	Fluoroquench
243	8	2	2	6					26-Mar	27-Mar	Yes		Yes			Biorad	30	60	Fluoroquench
245		1	1	4	1	1	1	4	26-Mar	26-Mar	Yes	Yes	No	100	100	BAG	45	60	EB/AO
252	2-4	2-4	2	4-6	2-4	2-4	2	4-5	27-Mar	27-Mar		Yes	Yes	30		Biorad	30	60	
259									27-Mar	27-Mar	Yes	Yes	Yes	90	85	Biorad	30	60	AO/PI
260	++++				++++				27-Mar	27-Mar		Yes	Yes	90		Biorad	30	60	EB/AO
262	4-6								26-Mar	26-Mar	Yes	Yes	Yes	95	95	Invitrogen	30	60	Eosin
268	8	1	1	4	1	1	1	6	26-Mar	27-Mar		Yes	No	85		Gentrak	30	60	EB/AO
271	6	1	1	6					27-Mar	27-Mar		Yes	Yes	95		One Lambda	30	60	EB/AO
284	8	1	1	8	1	1	1	6	26-Mar	27-Mar		Yes	Yes	98		Cedarlane	40	60	EB/AO
293	6								27-Mar	27-Mar		Yes	Yes	70		Invitrogen	60	120	Eosin
294	0	0	0	6					26-Mar	26-Mar		Yes	Yes	100		Life Technologies	30	30	Fluoroquench
297	8	1	1	4	1	1	1	4	26-Mar	27-Mar	Yes	Yes	Yes	70	70	Cedarlane	30	60	EB/AO

AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A31; B44, B35; Cw4, - ; DR1, DR7; DQ2, DQ5

Summary of Results					Summary of Results				
Total tested	31	30	29	31	23	24	23	24	
Positive	28	2	2	20	3	0	1	14	
Negative	3	28	27	11	20	24	22	10	
Not Tested	6	7	7	6	0	0	0	0	
% Positive	90.3%	6.7%	6.9%	64.5%	13.0%	0.0%	4.3%	58.3%	
% Negative	9.7%	93.3%	93.1%	35.5%	87.0%	100.0%	95.7%	41.7%	
Consensus	Positive	Negative	Negative	Not Assessed	Negative	Negative	Negative	Not Assessed	
HLA Antibody (Defined By CDC)	A2, B17	DR3	DR3	B14+					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
120	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Few cells, but 100% viability
139	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
145	Positive	Negative	Negative	Positive					The evaluation of XM using B-cell was difficult due to the very low number of B-cells
147	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
154	Positive	Negative	Negative	Negative					
159	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
164	Positive	Positive	Positive	Positive	Positive	Negative	Positive	Positive	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	NT	NT	NT	NT					No sufficient material available
186	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
190	NT	NT	NT	NT					Samples not tested due to the number and viability of the cells
193	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
195	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
197	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
204	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
206	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
209	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	NT	NT	NT	NT					
223	NT	NT	NT	NT					Not tested due to low viability
227	NT	NT	NT	NT					Not tested due to poor viability
238	NT	NT	NT	NT					Impossible to read for B-cells
243	Positive	NT	Negative	Positive					Serum 2 - Insufficient cells to interpret
245	Positive	Negative	Equivocal	Positive	Equivocal	Negative	Equivocal	Positive	
252	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
259	Positive	Positive	Positive	Positive					
260	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
262	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
271	Positive	Negative	NT	Positive					Unable to interpret B-cell CDC crossmatch
284	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
293	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
294	Positive	Negative	Negative	Positive					
297	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	

PLEASE NOTE: NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	4	1	1	1	1	1	1	1	27-Mar	27-Mar	Yes		One Lambda	30	60	EB/AO
120	8	1	1	1	1	1	1	1	27-Mar	27-Mar	Yes	100	Servibio	30	60	EB/AO
126	50-75%								26-Mar	26-Mar	Yes	100	Cedarlane	30	40	EB/AO
139	8	1	1	4	1	1	1	4	31-Mar	31-Mar	Yes	90	Cedarlane	30	60	Eosin
145	8			6-8					26-Mar	27-Mar	Yes	100	Invitrogen	45	45	EB/AO
147	8	1	1	4	1	1	1	4	26-Mar	26-Mar	Yes	100	In-house	30	60	Fluoroquench
154	6	1	1	1					25-Mar	27-Mar	No	90	Cedarlane	30	60	Eosin
159	8	1	1	1	1	1	1	1	27-Mar	27-Mar	Yes	80	In-house	30	60	Fluoroquench
162	8			4-6				4-6	26-Mar	27-Mar	Yes	100	Cedarlane	60	60	
164									26-Mar	27-Mar	Yes	70	Servibio	45	90	EB/AO
169	1	1	1	1	1	1	1	1	27-Mar	28-Mar	Yes	60	One Lambda	35	75	Fluoroquench
181	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	27-Mar	Yes	100				
186	8	0	0	6	0	0	0	4	27-Mar	27-Mar	Yes	99	Invitrogen	30	60	EB
190	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	27-Mar	Yes	70	Cedarlane	30	60	Fluoroquench
193	8	1	1	1	1	1	1	1	26-Mar	26-Mar	Yes	99	Cedarlane	30	60	Fluoroquench
194	8	1	1	6	1	1	1	6	26-Mar	26-Mar	Yes	95	In-house	30	45	Fluoroquench
195	6	2	2	8	2	2	2	8	28-Mar	28-Mar	Yes	40	Invitrogen	60	90	Fluoroquench
197	Weak				Weak				27-Mar	28-Mar	Yes	80	One Lambda	30	60	Fluoroquench
204	6	1	1	6	1	1	1	6	26-Mar	26-Mar	Yes	75	Cedarlane	45	90	Fluoroquench
206	8	1	1	4	1	1	1	1	26-Mar	27-Mar	Yes	90	Cedarlane	30	45	Fluoroquench
209	6								27-Mar	27-Mar	Yes	98	Ingen	30	60	Fluoroquench
210																
223	NT	NT	NT	NT					27-Mar	28-Mar	Yes		Biorad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	26-Mar	Yes	50	Immucor	30	60	Fluoroquench
238	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	27-Mar	NT	NT	NT	NT	NT	NT
243	6	NT	2	Weak					26-Mar	27-Mar	Yes	80	Biorad	30	60	Fluoroquench
245	8	1		4		1		4	26-Mar	26-Mar	Yes	100	BAG	45	45	EB/AO
252	2-4	2-4	2	4-6	2-4	2-4	2	4-6	27-Mar	27-Mar	Yes		Biorad	30	60	
259									27-Mar	27-Mar	Yes	80	Biorad	30	60	AO/PI
260	++++				++++				27-Mar	27-Mar	Yes	60	Biorad	30	60	EB/AO
262	8			4				4	26-Mar	26-Mar	Yes	40	Invitrogen	60	90	Eosin
268	1	1	1	1	1	1	1	1	26-Mar	27-Mar	Yes	85	Gentrak	30	60	EB/AO
271	8	1	NT	8					27-Mar	27-Mar	Yes	40	One Lambda	30	60	EB/AO
284	8	1	1	4	1	1	1	6	26-Mar	27-Mar	Yes	90	Cedarlane	40	60	EB/AO
293	8			4				4	27-Mar	27-Mar	Yes	50	Invitrogen	60	120	Eosin
294	4	0	0	4					26-Mar	26-Mar	Yes	95	Life Technologies	30	30	Fluoroquench
297	8	1	1	4	1	1	1	4	26-Mar	27-Mar	Yes	70	Cedarlane	30	60	EB/AO

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate